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Abstract 
Background: To reduce onward falciparum malaria transmission, the World Health Organization recommends add-
ing single low-dose (SLD) primaquine to artemisinin-based combination treatment in low transmission areas. How-
ever, uptake of this recommendation has been relatively slow given concerns about whether individual risks justify 
potential community benefit. This study was undertaken to generate comprehensive local data on the risk–benefit 
profile of SLD primaquine deployment in a pre-elimination area in South Africa.
Methods: This randomized, controlled open-label trial investigated adding a single low primaquine dose on day 3 to 
standard artemether–lumefantrine treatment for uncomplicated falciparum malaria. Efficacy, safety and tolerability of 
artemether–lumefantrine and primaquine treatment were assessed on days 3, 7, 14, 28 and 42. Lumefantrine concen-
trations were assayed from dried blood spot samples collected on day 7.
Results: Of 217 patients screened, 166 were enrolled with 140 randomized on day 3, 70 to each study arm (pri-
maquine and no primaquine). No gametocytes were detected by either microscopy or PCR in any of the follow-up 
samples collected after randomization on day 3, precluding assessment of primaquine efficacy. Prevalence of the 
CYP2D6*4, CYP2D6*10 and CYP2D6*17 mutant alleles was low with allelic frequencies of 0.02, 0.11 and 0.16, respec-
tively; none had the CYP2D6*4/*4 variant associated with null activity. Among 172 RDT-positive patients G6PD-geno-
typed, 24 (14%) carried the G6PD deficient (A−) variant. Median haemoglobin concentrations were similar between 
treatment arms throughout follow-up. A third of participants had a haemoglobin drop > 2 g/dL; this was not associ-
ated with primaquine treatment but may be associated with G6PD genotype [52.9% (9/17) with A− genotype vs. 
31% (36/116) with other genotypes (p = 0.075)]. Day 7 lumefantrine concentrations and the number and nature of 
adverse events were similar between study arms; only one serious adverse event occurred (renal impairment in the 
no primaquine arm). The artemether–lumefantrine PCR-corrected adequate clinical and parasitological response rate 
was 100%, with only one re-infection found among the 128 patients who completed 42-day follow-up.
Conclusions: Safety, tolerability, CYP2D6 and G6PD variant data from this study support the deployment of the WHO-
recommended SLD primaquine without G6PD testing to advance malaria elimination in South African districts with 
low-intensity residual transmission.
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Background
It is widely acknowledged that novel tools and strategies 
are required to eliminate foci of residual Plasmodium 
falciparum malaria transmission [1, 2]. One strategy put 
forward by the World Health Organization (WHO) is re-
purposing primaquine [3–5], the anti-malarial currently 
recommended for radical cure of relapsing Plasmodium 
vivax and Plasmodium ovale malaria [5]. A review of 
existing data showed single low-dose (SLD) primaquine 
to be highly effective against mature gametocytes (the 
natural transmissible parasite stage) [6], thus reducing 
gametocyte circulation time [7] and malaria transmis-
sion to mosquitoes [8]. While artemisinin-based com-
bination therapy (ACT) rapidly clears asexual parasites 
and early stage gametocytes [9, 10], it is only partially 
effective against mature gametocytes, allowing gameto-
cytes to persist and remain infectious for up to 14  days 
after treatment [11], thereby sustaining the transmission 
cycle [12]. To halt onward P. falciparum transmission, the 
WHO recommended that SLD primaquine be added to 
the standard ACT treatment in low transmission areas, 
particularly as a component of elimination or pre-elimi-
nation strategies and in areas threatened by resistance of 
P. falciparum to artemisinins [3–5].
Despite the obvious gametocytocidal benefits of pri-
maquine, its uptake has been relatively slow given con-
cerns about whether individual risks justify potential 
community benefit. Safety concerns relate to haemolytic 
toxicity seen with the higher primaquine doses required 
for radical cure of P. vivax and P. ovale malaria, particu-
larly in glucose-6-phosphate dehydrogenase (G6PD)-
deficient individuals [13, 14]. This X-linked deficiency 
increases red blood cell susceptibility to oxidative stress 
and thus haemolysis, and is prevalent in malaria-endemic 
tropical and sub-tropical regions as it is protects against 
severe malaria [15, 16]. Severity of haemolysis depends 
on the G6PD variant present, gender, as well as dose 
and duration of primaquine exposure [17]. The G6PD 
gene is highly polymorphic, resulting in over 400 G6PD 
variants with enzyme activities ranging from normal to 
highly deficient [18]. Three variants, B, A+ and A− are 
most frequently found across sub-Saharan Africa [19]. 
The wild-type B variant and A+ variant (which carries a 
single mutation at nucleotide 376), have normal or near-
normal enzyme activities. With an additional mutation at 
nucleotide 202, the A− variant has approximately 12% of 
the wild type enzyme activity [20] and is generally associ-
ated with mild haemolysis [21, 22]. Previous studies have 
shown the A− variant occurs at frequencies between 2 
and 9% in South Africa [23, 24].
The gene coding for the cytochrome P450 2D6 
(CYP2D6) enzyme, responsible for metabolic activation 
of primaquine, is highly polymorphic. These polymor-
phisms are associated with inter-individual variations 
in the therapeutic efficacy and haemolytic effects of 
primaquine [25–27] and display marked inter-ethnic 
frequency differences [28, 29]. The CYP2D6*10 and 
CYP2D6*17 variants more often detected in Asian and 
African populations, respectively, are associated with 
intermediate metabolizer status, while the CYP2D6*4 
variant more frequently found in Caucasians is associ-
ated with a poor metabolizer status and total loss of 
CYP2D6 function in homozygous carriers [29–31]. Pre-
vious research has confirmed that the CYP2D6*17 vari-
ant is widespread across Africa [32], ranging in frequency 
from 1 to 33% [33].
With a national malaria incidence of less than one 
case per 1000 population at risk since the mid-2000s, 
[34], South Africa officially transitioned to an elimina-
tion agenda in 2012 [35]. Although adequate coverage of 
the existing interventions has largely been achieved [36], 
residual local transmission persists, impeding the coun-
try’s progress towards elimination. The National Malaria 
Directorate is considering deploying SLD primaquine 
in these foci of residual transmissions but has expressed 
concerns over the lack of local data to guide implemen-
tation. This study was therefore undertaken to generate 
comprehensive local data to inform the risk–benefit pro-
file of SLD primaquine deployment in a pre-elimination 
area within South Africa. Efficacy, safety and tolerability 
in those randomized to receive primaquine in addition to 
standard artemether–lumefantrine treatment of uncom-
plicated falciparum malaria was compared to those ran-
domized to receive standard artemether–lumefantrine 
treatment alone. Updated information was generated 
on the prevalence of anaemia and the different G6PD 
and CYP2D6 variants in the target population. In addi-
tion, the impact SLD primaquine had on gametocyte car-
riage in an area of very low transmission intensity was 
assessed, as African studies to date have mostly been 
conducted in areas where more intense malaria transmis-
sion facilitates recruitment [37–39]. Lastly, the study also 
Trial registration Pan African Clinical Trial Registry, PACTR201611001859416. Registered 11 November 2016, https ://
pactr .samrc .ac.za/Trial Displ ay.aspx?Trial ID=1859
Keywords: Primaquine, Artemether–lumefantrine, Efficacy, Safety, Tolerability, Gametocyte carriage, South Africa, 
Plasmodium falciparum
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compared lumefantrine concentrations on day 7 between 
those randomized to receive primaquine and no pri-
maquine, and provided the opportunity to re-assess the 
therapeutic efficacy of artemether–lumefantrine, which 
has been first-line treatment in the study area for over a 
decade.
Methods
Study aim, design and setting
This randomized, controlled, allocation-concealed open-
label trial investigated the efficacy, safety and tolerabil-
ity of adding a single low primaquine dose to standard 
artemether–lumefantrine treatment. The clinical trial was 
conducted at Komatipoort and Naas primary healthcare 
facilities that serve a population of approximately 10,000 
people in Nkomazi sub-district, Mpumalanga Province, 
South Africa. During the 2017–2018 financial year the 
sub-district reported 3438 malaria cases, of which only 
626 were classified as locally transmitted. Malaria trans-
mission in the area is unstable and seasonal, occurring 
predominately during the wet summer months from Sep-
tember to May. Major peaks in transmission are gener-
ally observed in January and after Easter, which coincide 
with increased population movement across the border 
shared with Mozambique [40]. The predominant malaria 
parasite is P. falciparum with the main vector Anopheles 
arabiensis. In line with national malaria diagnostic and 
treatment guidelines [41, 42], these nurse-run healthcare 
facilities offer routine malaria testing using P. falciparum-
specific malaria HRP2 antigen-based rapid diagnostic 
test (RDT) kits (First  Response®, Premier Medical Cor-
poration, India) and treat uncomplicated malaria with 
artemether–lumefantrine  (Coartem®, Novartis Pharma, 
South Africa). Insecticide-based indoor residual spraying 
is the primary vector control intervention [43].
Study participants
Individuals aged ≥ 2 years and weighing ≥ 10 kg present-
ing with a fever (or history of fever in the past 48 h) were 
screened for eligibility only if they intended to remain in 
the study area throughout the 6-week follow-up period. 
When the study health facilities were over-loaded, poten-
tial participants were pre-screened for malaria by RDT 
according to routine practice. Exclusion criteria were rel-
atively strict as primaquine is not currently licensed for 
use in South Africa, and were: being malaria RDT-nega-
tive, evidence of severe illness, and concurrently receiv-
ing other drugs that may cause haemolysis, bone marrow 
suppression or QTc interval prolongation, known allergy 
to study drugs, any anti-malarial use within the past 
4 weeks, blood transfusion within the last 90 days, hae-
moglobin concentration (Hb) < 7  g/dL, history of hae-
molysis, rheumatoid arthritis, lupus erythematosus, 
cardiac disease, and currently menstruating, pregnant or 
breastfeeding. Prior to being screened for the trial, writ-
ten informed consent was obtained from all consenting 
participants aged ≥ 18 years, while consent was provided 
by parents or guardians of individuals younger than 
18  years. Assent was also obtained from children aged 
≥ 7  years, with literate witnesses included for patients 
who could not read.
Study drugs, randomization and dosing
All enrolled participants were treated with artemether–
lumefantrine, administered as the standard 6-dose, 
weight-based regimen [5, 42]. Participants were given 
a diary card to record the time of dosing, whether they 
vomited and what food or drink was taken with each 
dose. They were encouraged to take all doses with milk or 
food [44] but were asked to return any doses not taken.
On day 3 participants were randomized in a 1:1 ratio 
to artemether–lumefantrine alone (standard of care) or 
artemether–lumefantrine plus primaquine (Primaquine 
Phosphate  Tablets®, Sanofi Aventis, South Africa), pro-
vided their haemoglobin (Hb) had not decreased by > 2 g/
dL from day 0 (unless day 3 Hb ≥ 10 g/dL), and were oth-
erwise eligible to continue. A primaquine target dose of 
0.25  mg/kg was administered according to  the WHO 
weight-based dosing recommendations [5]. A randomly-
generated sequence of treatment numbers, stratified 
by clinic, was prepared by an independent statistician 
using the “rand()” function in Microsoft  Excel®, who 
was the only person with access to the randomization 
schedule and who was not involved in participant assess-
ments. Clinics were instructed to open the next available 
sequentially-numbered opaque envelope if the patient 
was eligible for primaquine dosing. Each envelope con-
tained a piece of paper indicating if the participant was 
randomized to receive primaquine or no primaquine. For 
children, the dose of primaquine was crushed in water 
and given in an oral syringe according to the manufac-
turer-approved extemporaneous preparation procedure. 
Doses of artemether–lumefantrine and primaquine were 
repeated if the participant vomited within 30  min, and 
participants withdrawn if vomiting persisted thereafter.
Clinical procedures
Participants were asked about previous and current med-
ical conditions during screening, and use of medicines 
(allopathic, traditional, complementary) throughout the 
study. Demographic data including age, gender, body 
weight, occupation, current area of residence, travel his-
tory, and country of origin were collected at screening, 
while vital signs (tympanic temperature, pulse rate, blood 
pressure and respiratory rate) were recorded at each visit. 
A physical examination was conducted at baseline as per 
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the standard of care. Thereafter, any physical examina-
tions were symptom-directed. Staff were specifically re-
trained in potential signs and symptoms of severe malaria 
and haemolysis.
As the type of questioning can influence the data col-
lected [45, 46], participants were asked about their health 
during the study according to a standard study-specific 
practice, to elicit participant-reported adverse events 
(AEs). Severity of AEs except fever were classified as: 
mild (awareness of symptoms that are easily tolerated and 
do not interfere with usual daily activity); moderate (dis-
comfort that interferes with or limits usual daily activity); 
or severe (disabling, with subsequent inability to perform 
usual daily activity, resulting in absence or required bed 
rest). Fever was categorized as mild (37.5–38.0 °C); mod-
erate (> 38.0 to 39.0 °C); or severe (> 39.0 °C). Seriousness 
of an AE was categorized as per ICH E2A [47], with a Hb 
drop of ≥ 40% of baseline Hb and/or requiring a blood 
transfusion, and/or Hb values of ≤ 5  g/dL included as 
serious adverse events (SAEs). The relationship of AEs 
with primaquine was assessed as not related, unlikely, 
possible, probable and unassessable/unclassifiable. All 
AEs were then coded using the Medical Dictionary for 
Regulatory Activities (MedDRA) terminology, version 20 
[48].
Haemoglobin level was assessed at each visit by fin-
ger-prick blood sample using a  HemoCue® photometer 
(Ängelholm, Sweden) and haemoglobinuria tested for 
with a urine dipstick. G6PD enzyme activity was assessed 
for all enrolled participants using the G6PD Biosensor 
Analyser (Care Start, AccessBio, New Jersey, USA).
On day of enrolment and each subsequent visit (sched-
uled or unscheduled), duplicate thick and thin blood 
smears and three dried blood spots (DBS) on Munktell 
TFN filter-paper cards (Munktell, Germany) were col-
lected. One set of thick and thin smears were sent directly 
to the Mpumalanga Provincial Malaria Laboratory for 
staining and reading, to inform eligibility and clinical 
management. The other set was couriered with the indi-
vidually packaged DBS to the Parasitology Reference 
Laboratory at the National Institute for Communicable 
Disease (NICD) for analysis. On day 7 an additional three 
50 µL dried blood spots were collected via lithium hepa-
rin microcapillary tubes onto Whatman 31ET CHR filter 
paper pre-treated with tartaric acid for lumefantrine con-
centration assays at the University of Cape Town (UCT).
Microscopy
Malaria microscopy was performed according to 
national malaria diagnostic guidelines [41]. Asex-
ual parasites were counted against 200 white blood 
cells (WBC) for high parasitaemias (≥ 100 parasites 
observed) or 500 WBC for low parasitaemias (< 100 
parasites observed). A slide was considered negative 
if no parasites were observed after 200 fields had been 
examined. Every slide was read by two independent 
microscopists. If the parasite densities differed by more 
than 25%, or if there were discordant results, an addi-
tional reading was performed by a third independent 
microscopist. An average of the two closest readings 
was taken as the final result.
Molecular analysis
Parasite RNA was extracted from the filter-paper blood 
samples using the Qiagen RNeasy mini extraction kit 
(Qiagen, Germany). Gametocyte carriage was assessed 
using the reverse transcriptase-polymerase chain reac-
tion (RT-PCR) method to detect pfs25 transcripts with 
a detection limit of 1–2 gametocytes/µL as described by 
Mlambo et al. [49].
The Qiagen DNA mini extraction kit (Qiagen, Ger-
many) was used to extract parasite and human DNA 
from the filter-paper blood samples. Once confirmed 
as P. falciparum by multiplex polymerase chain reac-
tion (PCR) [50], polymorphism analysis of kelch13, crt 
and mdr1 genes was conducted. The propeller domain 
of the kelch13 gene was amplified using the protocol of 
Talundzic et  al. [51] and subjected to Sanger sequenc-
ing. Sequences obtained were aligned against a refer-
ence P. falciparum kelch13 gene (XM_001350122.1) 
using a BLAST search and BioEdit Software to identify 
25 specific alleles selected according to their association 
with prolonged parasite clearance half-lives [52]. Prim-
ers, PCR conditions and restriction endonucleases used 
to detect polymorphisms in the mdr1 (codon 86) and crt 
(codon 76) genes have been described previously [53, 
54]. The mdr1 gene copy number was assessed using a 
previously described qPCR method [55]. Multiplicity of 
infection was determined using the protocol of Ranford-
Cartwright et al. [56].
G6PD variant genotyping to detect the most common 
African variants, A+, A− and B [19] was performed 
using a previously published protocol [19]. Genotyping 
of the CYP2D6*4, 10* and *17 variants was conducting 
using the protocol of Naveen et al. [29]. A subset of sam-
ples was sent for sequencing to validate the PCR–RFLP 
protocols.
Lumefantrine concentration analysis
Pharmacokinetic assays were performed using a modifi-
cation of the method developed by Blessborn et al. [57]. 
The assay was optimized and validated at the UCT Divi-
sion of Clinical Pharmacology Analytical Laboratory. The 
lower limit of quantification was 0.0391 µg/mL.
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Data management and statistical analysis
Assuming a 10% loss to follow-up, a sample size of 70 
participants per arm will provide over 80% power at the 
0.05 significance level to detect at least a 50% reduction 
in RT-PCR gametocyte prevalence between study arms 
(e.g. 40% vs. 20% on day 7). This sample size would also 
be sufficient to detect a clinically significant (2  g/dL) 
decrease in mean Hb between study arms (e.g. 11 g/dL vs. 
9 g/dL). Although this sample size calculation assumed a 
slightly lower RT-PCR gametocyte baseline prevalence 
and smaller primaquine effect than Gerardin et  al. [10], 
the low prevalence of gametocytes from day 3 onwards 
precluded the assessment of efficacy in this study.
Clinical study data were collected using paper-based 
source documents, 100% of which were monitored for 
missing, unexpected and out-of-range dates and values. 
These data were entered into a REDCap electronic data 
management system hosted at UCT [58]. Source data 
verification was performed on 100% of the electronic 
data by the study team and a random sample of 10% 
by the trial sponsor; the UCT Clinical Research Centre 
sponsored this investigator-initiated study. The database 
was locked, and de-identified electronic datasets were 
exported to STATA version 15.1 (StataCorp, College Sta-
tion, Texas) for analysis once all outstanding data queries 
had been resolved. Molecular drug resistance marker, 
parasite, gametocyte, G6PD and CYP2D6 data from the 
NICD were  transferred to UCT as MSExcel worksheets 
for merging with the clinical STATA file. Although the 
translation of genotype information into metabolizer 
phenotype is challenging given the range of activity pos-
sible for each CYP2D6 allele, an ‘activity score’ (AS) was 
inferred from each CYP2D6 variant as described by Gae-
digk et al. [59]. Briefly, the AS represents the sum of val-
ues assigned to each individual allele according to their 
perceived function: non-functional alleles (CYP2D6*4) 
were given an AS value of 0, reduced-function alleles 
(CYP2D6*10 and CYP2D6*17) an AS value of 0.5 and 
functional alleles (CYP2D6*1 or wild-type) an AS value of 
1. Those with an activity score or 2.0 or 1.5 could be con-
sidered extensive metabolizers (EM), an activity score or 
1.0 or 0.5 intermediate metabolizers (IM), and an activity 
score of 0 poor metabolizers (PM) [30].
Results
Baseline characteristics
Between 14 December 2016 and 7 June 2018, 217 
patients with suspected malaria were screened. Of the 
181 malaria RDT-positive patients, 166 met the study cri-
teria and were enrolled. Of these, 140 were randomized 
on day 3, 70 to each study arm. A total of 128 (91%) par-
ticipants, 62 (89%) in the primaquine arm and 66 (94%) 
in the no primaquine arm, completed follow-up until day 
42 (Fig. 1).
Table  1 summarizes baseline characteristics for all 
screened who were malaria RDT-positive (considered 
representative of the target population) and for those 
randomized to primaquine or no primaquine. Base-
line characteristics of the participants in both treatment 
groups were similar for age, gender, bodyweight, hae-
moglobin, and asexual and gametocyte parasite density 
by microscopy. However, there was a higher prevalence 
of individuals carrying multiple P. falciparum clones 
(p = 0.042) and gametocytes by PCR (p = 0.03) in the pri-
maquine arm compared to the no primaquine arm. The 
median (IQR) primaquine dose administered in those 
randomized to primaquine was 0.25 (0.24–0.27) mg/kg.
G6PD variant prevalence
Among the 172 RDT-positive patients G6PD-genotyped, 
24 (14%) carried the G6PD deficient (A−) variant, with 
the remainder of the participants carrying the G6PD var-
iants associated with normal enzyme activity [B variant, 
110/172 (64%)] or mild deficiencies [A+ variant, 38/172 
(22%)], as shown in Table  2. Of the 24 patients with 
A− genotype, 17 were hemizygous males and 7 were het-
erozygous females. There was good correlation between 
the G6PD phenotypic screening data generated by the 
 CareStart® G6PD Biosensor and the genotypic data 
(Kruskall–Wallis p = 0.018). Biosensor readings of below 
30 were observed more frequently in individuals carry-
ing the A− variants than other genotypes [7/22, (31.8%) 
vs 16/138 (12.2%); p = 0.012]. The higher prevalence of 
the A− variant among those randomized to primaquine 
(11/66, 18%) than those not randomized to primaquine 
(6/67, 10%) had no statistical significance (p = 0.183).
CYP2D6*4, CYP2D6*10 and CYP2D6*17 variant prevalence 
and phenotype inference
Overall, among the 171 malaria RDT-positive patients 
genotyped, prevalence of the CYP2D6*4, CYP2D6*10 
and CYP2D6*17 mutant alleles was low with allelic fre-
quencies of 0.02, 0.11 and 0.16, respectively (Table  2). 
The majority [129/171 (75.4%)] had an activity score of 
2, with an activity score of 1.5 in 31 (18.1%) participants, 
an activity score of 1 in 10 (5.9%) participants, and an 
activity score of 0.5 in 1 participant (0.6%). None had the 
CYP2D6*4/*4 variant associated with null activity. Two 
subjects had heterozygous genotypes for all 3 variants 
tested (*4/*10/*17), similar to CYP2D6 genotypes previ-
ously described by Montané Jaime et al. [60].
Gametocyte carriage
Gametocyte carriage detected by microscopy and PCR 
on day 0 differed markedly, as expected, with PCR 
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detecting over 15-fold more gametocytes than micros-
copy (Table  1). By day 3, prior to randomization and 
primaquine administration, gametocyte carriage had 
decreased substantially with only two individuals, both 
in the primaquine arm, with gametocytes detected by 
PCR. No gametocytes were detected by either micros-
copy or PCR in any of the follow-up samples collected 
after randomization (from day 7 until day 42), preclud-
ing an assessment of the effect of primaquine on game-
tocyte carriage.
217 individuals screened for eligibility
51 excluded
36 RDT negave
7 prohibited meds
2 pregnant
1 Hb < 7g/dL
1 breast feeding
1 recent blood transfusion
1 relocang
1 not recruing day
1 severe malaria
166 individuals enrolled
140 randomised on day 3
26 excluded before day 3
14 missed day 3 visit
6 Hb drops of > 2g/dL
4 prohibited meds
1 Hb drop and prohibited 
med
1 SAE
70 did not receive primaquine70 received primaquine
62 completed safety and efficacy 
follow-up
66 completed safety and efficacy 
follow-up
8 lost to follow-up
0 SAE
0 withdrew consent
3 lost to follow-up
1 SAE
0 withdrew consent
Inial screening
Enrolment day 0
Randomisaon
Study drug
42 day follow-up 
for safety and 
efficacy
Fig. 1 Trial profile and patient disposition. SAE serious adverse event, Hb haemoglobin
Table 1 Patient characteristics at baseline and randomization
Categorical variables summarized as number (%); continuous variables summarized as median (IQR), unless otherwise stated
Total RDT positives 
screened [n = 181]
Randomized 
to primaquine [n = 70]
Not randomized 
to primaquine 
[n = 70]
Age (years) 32.1 (24.8–38.7) 32.2 (24.8–39.6) 32.4 (24.3–38.8)
Gender, female n (%) 55 (30.4) 22 (31.4) 16 (22.9)
Bodyweight (kg) 60 (55–64) 60 (53–63) 60 (55–64)
Day 0 haemoglobin (g/dL) 12.9 (11.3–14.2) 13.0 (11.6–14.5) 13.3 (11.6–14.5)
Day 0 anaemia (< 10 g/dL) 14/177 (7.9) 4/70 (5.7) 3/69 (4.4)
Day 3 haemoglobin (g/dL) 12.5 (11.2–13.7) 12.4 (11.3–13.9) 13.0 (11.7–13.6)
Day 3 anaemia (< 10 g/dL) 18/150 (12.0) 5/70 (7.1) 7/70 (10)
Day 0 asexual parasite density/per µL, geometric mean (95% CI) 5554 (3971–7768) 5048 (2933–8688) 4769 (2782–8175)
Day 0 multiplicity of infection (2 or more clones detected) 121/165 (73.3) 41/65 (63.1) 50/63 (79.4)
Day 0 gametocyte prevalence by microscopy 5 (2.3) 3 (4.3) 2 (2.9)
Day 0 gametocyte prevalence by PCR 109/176 (61.9) 48/69 (57.8) 35/68 (42.2)
Page 7 of 13Raman et al. Malar J          (2019) 18:209 
Haematological response
On day 3, haemoglobin concentrations among those 
enrolled but not randomized were  significantly lower 
(Kruskall–Wallis p < 0.0001), and the risk of anaemia 
significantly higher (6/10 vs 12/140; p < 0.001), com-
pared to the 140 participants randomized, reflecting 
the haemoglobin-based randomization criteria. Among 
those randomized, median Hb was slightly lower in the 
primaquine arm compared to the no primaquine arm, 
both before (day 0 and 3) and after (days 7–42) rand-
omization and primaquine dosing (Fig.  2). These dif-
ferences were however not statistically significant. 
The median Hb nadir occurred in both arms on day 
7 (Fig.  2). One third of participants had a drop in Hb 
from baseline of > 2  g/dL, but this was not associated 
with primaquine treatment [24/70 (34%) in the pri-
maquine arm and 23/69 (33%) in the no primaquine 
arm]. However, this drop in Hb may be associated with 
G6PD genotype (Fig. 2), as 52.9% (9/17) of participants 
with the A− genotype experienced such a drop in Hb 
compared to 31% (36/116) of participants with other 
genotypes (p = 0.075). Anaemia (defined as Hb < 10  g/
dL) was present at baseline in 4 individuals in the pri-
maquine arm and 3 participants in the no primaquine 
arm, and emerged during follow-up in 6/66 (9.1%) in 
the primaquine arm and 11/67 (16.4%) in the no pri-
maquine arm (p = 0.21). If the WHO standard (< 10.9 g/
dL for non-pregnant patients aged > 5 years [61]) rather 
than local current standard of care (< 10  g/dL) was 
used for the definition of moderate/severe anaemia, 
anaemia was more prevalent at each follow-up visit but 
remained similar between treatment arms.
Adverse events
A total of 74 AEs, other than the anaemia described 
above, occurred in 29% (40/140) of the participants 
randomized. Twenty-two (31%) participants in the pri-
maquine arm reported 45 AEs while 18 (26%) individu-
als in the no primaquine arm reported 29 AEs (Table 3) 
Differences in the number of AEs in each MedDRA sys-
tem order class by treatment arm was not statistically 
significant (p = 0.34). The majority of AEs were mild, 
with only one serious AE (SAE) occurring during the 
trial. The SAE (in the no primaquine arm) was a case of 
severe renal impairment (estimated glomerular filtration 
rate, eGFR, of 6 mL/min/1.73 m2) detected on day 14 in 
an adult male with a poorly defined, initially undisclosed 
medical history of renal impairment. The patient’s eGFR 
improved to 24 mL/min/1.73 m2 by day 42, and 27 mL/
min/1.73  m2 3  months later. Eleven moderately-severe 
AEs (5 in the primaquine arm and 6 in the no primaquine 
arm) were recorded. Of the five moderately severe AEs in 
the primaquine arm (1 each of post-dose vomiting, chest 
pain, headache, urinary tract infection and sexually trans-
mitted infection), the post-dose vomiting was classified 
as probably associated with primaquine, the headache as 
possibly associated with primaquine, and the others as 
unlikely/not related to primaquine. Among those rand-
omized to primaquine, there was no difference between 
extensive and intermediate CYP2D6 metabolizers in 
Table 2 Glucose-6-phosphate dehydrogenase (G6PD) genotype and  phenotype and  cytochrome P450 2D6 (CYP2D6) 
genotype and activity scores among RDT-positive participants screened and randomized; n (%)
a CYP2D6 activity score is the sum of the per-allele scores; a null allele having a score of 0, a deficient allele a score of 0.5 and a normal allele a score of 1. CYP2D6 poor 
metabolizers (PM AS = 0), intermediate metabolizers (IM AS 0.5–1.0), extensive metabolizers (EM AS 1.5–2.0) [30, 31]
Total RDT positives screened 
[n = 181]
Randomized to primaquine [n = 70] Not randomized 
to primaquine 
[n = 70]
G6PD variant genotype
 A− 24 (14.0) 11 (16.7) 6 (9.0)
 A+ 38 (22.1) 9 (13.6) 17 (25.4)
 B 110 (64.0) 46 (69.7) 44 (65.7)
G6PD phenotype (U/dL) 73 (51–91) 68 (51–89) 74 (40–90)
CYP2D6 variant genotype (activity score,  ASa)
 *1/*1 (AS 2.0; EM) 129 (74.4) 48 (71.6) 49 (74.2)
 *1/*10 (AS 1.5; EM) 13 (7.6) 5 (7.5) 5 (7.6)
 *1/*17 (AS 1.5; EM) 18 (10.5) 8 (11.9) 8 (12.1)
 *1/*4 (AS 1.0; IM) 1 (0.6) 1 (1.5) 0 (0)
 *10/*17 (AS 1.0; IM) 3 (1.8) 2 (3.0) 0 (0)
 *17/*17 (AS 1.0; IM) 4 (2.3) 2 (3.0) 2 (3.0)
 *4/*10 (AS 0.5; IM) 1 (0.6) 0 (0) 1 (1.5)
 *4/*10/*17 (AS 1.0; IM) 2 (1.2) 1 (1.5) 1 (1.5)
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terms of the occurrence of any adverse events (22/61 
vs 2/6; p = 0.89). No poor metabolizers were enrolled 
(Table 2).
Therapeutic efficacy of artemether–lumefantrine
Of the 151 participants seen on day 3, none were found 
to be carrying asexual parasites by microscopy and none 
met the WHO criteria for early treatment failure. How-
ever, by PCR, seven participants (five in the primaquine 
arm and two in the no primaquine arm) were identi-
fied with sub-microscopic asexual parasite carriage 
on day 3 with only one (in the primaquine arm) having 
sub-microscopic asexual parasites detectable on day 7. 
Among the 128 who completed 42-day follow-up, there 
was one late treatment failure in the primaquine arm (a 
late parasitological failure with an asexual parasite den-
sity of 390/μL but no fever on day 42). Genotype analysis 
by PCR showed this single treatment failure to be a new 
11
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Fig. 2 Median haemoglobin (g/dL) concentrations over time, by treatment arm (artemether–lumefantrine plus primaquine (solid lines) and 
artemether–lumefantrine alone (No Primaquine—dashed lines)) and G6PD status (G6PD normal (B or A+ variant—black lines) and G6PD deficient 
(A− variant—grey lines) with the arrow indicating day 3 when randomization and primaquine treatment occurred. G6PD: glucose-6-phosphate 
dehydrogenase
Table 3 Adverse events reported, by treatment arm
JVP jugular venous pressure, HIV human immunodeficiency virus
Primaquine No 
primaquine
Nervous system disorders: headache 13 6 7
Gastrointestinal: abdominal pain 7, vomiting 3, diarrhoea 1 5 6
Infections: urinary tract infections 5, flu 4, sexually transmitted diseases 3; 1 each eye 
abscess, tonsillitis, helminths, herpes zoster, malaria recurrence
13 4
Other: general body pains 17, chest pain 3; 1 each cough, dyspnoea, dysmenorrhea, vagi-
nal discharge, dysuria, haematuria, ketonuria, raised JVP, feeling hot, peripheral swelling, 
eye allergy, ear pain, HIV test positive
21 12
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infection, giving a PCR-corrected adequate clinical and 
parasitological response rate of 100%.
Molecular markers associated with artemether 
and lumefantrine resistance
All parasite isolates analysed were wild-type (164/164) 
at the 25 Kelch13 propeller domain alleles assayed, i.e. 
none of these parasites had mutations associated with 
artemisinin resistance. However, all 162 isolates had 
molecular markers associated with reduced lumefantrine 
susceptibility (wild-type crt76LYS and mdr186ASN); 
one of these isolates (1/165) carried both the wild and 
mutant crt76 alleles. Fortunately, none of the 162 isolates 
assessed for mdr1 copy number had the increased copy 
number associated with lumefantrine resistance.
Day 7 lumefantrine concentrations
Among the 140 patients randomized, lumefantrine con-
centrations could be determined for 114 participants (56 
from the primaquine arm and 58 from the no primaquine 
arm). Three concentrations were below the limit of quan-
tification (1 in primaquine arm and 2 in no primaquine 
arm); these were assumed to be 19.5 ng/mL, i.e. half the 
lower limit of quantification [62]. The median (interquar-
tile range) lumefantrine concentrations were found to 
be similar for both primaquine and no primaquine arms 
[291 (156–559) vs. 343 (180–502) ng/mL, p = 0.95]. Sim-
ilar results were obtained if the 7 participants who had 
their pharmacokinetic sample collected outside of the 
protocol window of day 7 ± 2  days were excluded [329 
(179–604) vs. 343 (181–492) ng/mL, p = 0.69].
Day 7 concentrations of below 200  ng/mL previ-
ously reported to be sub-optimal and associated with an 
increased risk of treatment failure [63]. Similar propor-
tions of participants between arms were found to have 
suboptimal day 7 concentrations 18/56 (32%) in the pri-
maquine arm and 18/58 (31%) in the no primaquine arm 
[p = 0.90]. Again, similar results were obtained if the 7 
participants who had their pharmacokinetic sample col-
lected outside of the protocol window of day 7 ± 2 days 
were excluded [15/51 (28%) vs. 17/56 (28%); p = 0.92].
Discussion
This is the first comprehensive controlled study on the 
risk benefit profile of SLD primaquine as a gametocyto-
cide conducted in a pre-elimination setting in sub-Saha-
ran Africa. Although this study was unable to confirm the 
efficacy previously demonstrated in larger studies, close 
monitoring of study participants confirmed the safety and 
tolerability of SLD primaquine in the local study popula-
tion, including in 17 patients who carried the G6PD A− 
variant associated with an increased risk of haemolytic 
anaemia when exposed to 8-aminoquinolines. Unlike 
previous studies [38, 63–66] that found the percentage 
decreases in Hb and haemoglobinuria/dark urine to be 
more likely in individuals receiving low-dose primaquine 
compared to no primaquine, data from this relatively 
small but detailed study appears to indicate that marked 
decreases in Hb were linked to malaria infection itself 
(with a significant drop in Hb before primaquine rand-
omization and administration on day 3) and G6PD vari-
ant rather than primaquine treatment. Only two of the 
previous studies used the 0.25  mg/kg primaquine dose 
[64, 66] while the others treated patients at a higher dose. 
Distinguishing malaria-related and primaquine effects is 
more challenging in studies that administer primaquine 
on day 0 rather than day 3. All Hb decreases in G6PD 
A− individuals were transient, supporting the Cochrane 
review conclusion that low-dose primaquine probably 
has little or no effect on severe haemolysis [63].
The low prevalence of individuals carrying the G6PD 
A− variant, associated with moderate G6PD deficiency 
[18], detected in this study concurs with data from a 
recent study conducted in neighbouring Limpopo Prov-
ince [67]. Unlike the current study’s majority Mozam-
bican (Shangaan) population, most individuals in the 
Limpopo study self-identified as South African Venda; 
this suggests the A− variant is relatively rare across a 
range of different ethnic groups in southern Africa. The 
absence of any variant associated with reduced G6PD 
activity in Eswatini [68], supports this interpretation.
In line with previous studies [38, 64–66, 69–71], no 
difference in adverse events between the study arms was 
observed, with most AEs classified as mild. No differ-
ence was observed in the occurrence of adverse events 
between CYP2D6 extensive and intermediate metabo-
lizers on primaquine; however, no poor metabolizers 
and few intermediate metabolizers were enrolled so it is 
not possible to draw any conclusion on the impact of the 
CYP2D6 phenotype on safety from these data. The sin-
gle serious adverse event, renal impairment, occurred in 
a patient who did not receive SLD primaquine and who 
had a  poorly defined history of ‘kidney problems’. This 
was unfortunately not detected during screening as the 
patient did not divulge a complete medical history ini-
tially and the medical records were not available (as is fre-
quently the case with mobile and migrant populations). 
The previously-reported increased frequency of ano-
rexia among participants treated with SLD primaquine 
[63] was not observed in this study. This could be the 
result of having a study population skewed towards ade-
quately-nourished adults who sought malaria treatment 
promptly, and the administration of primaquine on day 
3 by when malaria symptoms would usually have abated.
Unfortunately, this relatively small study was unable to 
demonstrate the efficacy of SLD primaquine in reducing 
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gametocyte carriage in an area of extremely low residual 
transmission. While more than half of the participants 
carried (mostly sub-microscopic) gametocytes at base-
line, very few were still gametocytaemic on day 3 when 
randomization to the primaquine/no primaquine arms 
took place. This negligible gametocyte carriage post-ACT 
may reflect the success of behaviour-change campaigns 
run by the Mpumalanga Malaria Elimination Programme 
to encourage early treatment seeking, within 24–48 h of 
the onset of malaria symptoms, when any gametocytes 
present are likely to be in the early stages of development 
and susceptible to artemisinin derivatives. The absence 
of CYP2D6 variants with null activity and the low preva-
lence of variants with slow and intermediate metabolism 
of inactive primaquine to its active metabolite would 
infer good primaquine efficacy in the local population. 
However, the patients enrolled in this study, who were 
symptomatic and willing to remain in the study area 
throughout the 6-week follow-up period, are not fully 
representative of the large mobile and migrant popula-
tions that are considered key drivers of ongoing malaria 
transmission in these areas. These mobile and migrant 
populations are often asymptomatic and are less likely to 
be willing to remain in the area for 6-weeks of follow-up 
[72]. Although dosing on day 3 is preferred for distin-
guishing primaquine-related adverse effects from malaria 
related events, it may not be the optimal time of dosing 
for malaria transmission blocking. Thus, the failure to 
demonstrate efficacy in this relatively small study should 
not detract from the potential for SLD primaquine to 
greatly reduce secondary transmission in the study area 
and similar areas working towards malaria elimination. 
Efficacy of SLD primaquine against mature gametocytes 
and reduction in infectiousness has previously been well 
established, including in a recent systematic review of 
larger studies [63]. This showed that the effect on infec-
tiousness precedes the effect of SLD primaquine on 
gametocyte prevalence, but that there is no evidence yet 
on whether SLD primaquine could reduce malaria trans-
mission at community level.
In light of the growing concerns over the sustained effi-
cacy of artemether–lumefantrine in the southern African 
region [73, 74], it was reassuring that this study reported 
a 100% PCR-corrected adequate clinical and parasi-
tological response. However, almost 90% of the study 
participants were adults who declared themselves as 
Mozambican nationals and over two-thirds were found 
to have two or more P. falciparum clones present at base-
line, suggesting that acquired premunition may have 
contributed substantially to this high cure rate. Geno-
typic analyses in this and other southern Africa stud-
ies [73, 75] have revealed strong selection for molecular 
markers linked with increased tolerance to lumefantrine 
[76]. Fortunately, an increase in Pfmdr1 gene copy num-
ber (associated with lumefantrine resistance) was not 
observed in this study and is rare in the region [73, 75, 
77]. Although artemisinin-resistant parasites have rap-
idly spread across the greater Mekong region [78, 79] and 
are most recently reported in India [80], to date there 
have been no confirmed reports of artemisinin-resist-
ant parasites becoming established in Africa. Reduced 
lumefantrine susceptibility would increase pressure 
on the artemisinin component of ACT, particularly in 
non-immune individuals. It is, therefore, imperative to 
enhance anti-malarial resistance surveillance across the 
southern Africa region to ensure effective treatment 
policies.
As a limited number of young children were recruited 
into the trial, the effects of SLD primaquine were not 
rigorously assessed in this population locally—although 
there is no reason to believe that these children would 
respond differently to those studied elsewhere. As pri-
maquine is not yet licensed for use in South Africa, the 
study’s inclusion and exclusion criteria were stricter 
than considered necessary by the WHO or that would 
be used when this intervention is rolled out to advance 
malaria elimination. However, some evidence of a reas-
suring safety profile in the broader target population was 
generated by defining the prevalence of anaemia and 
G6PD/CYP2D6 genotypes among all those screened. 
Budgetary constraints restricted drug resistance assess-
ments to a finite number of molecular markers primarily 
associated with resistance to artemether–lumefantrine. 
This prevented the generation of detailed drug sensitiv-
ity profiles and the possible detection of novel mutations 
which may affect drug efficacy.
Conclusion
Safety, tolerability, CYP2D6 and G6PD variant data from 
this study support the deployment of the WHO-recom-
mended SLD primaquine without G6PD testing in South 
African districts with low-intensity residual transmis-
sion aiming to eliminate malaria. Prior to its roll-out, 
all health care workers should receive comprehensive 
training on SLD primaquine use with robust pharma-
covigilance to strengthen data on primaquine safety in 
vulnerable populations. The risk of artemisinin resistance 
spreading from South East Asia to Africa and the strong 
selection for lumefantrine-tolerant parasites locally and 
regionally, emphasizes the need for regular and rigorous 
drug efficacy monitoring.
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